| 3.54 0.22 (6.63%) | 04-22 12:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.18 | 1-year : | 4.88 |
| Resists | First : | 3.57 | Second : | 4.18 |
| Pivot price | 0 | |||
| Supports | First : | 3.41 | Second : | 3.31 |
| MAs | MA(5) : | 0 | MA(20) : | 0 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0 | Signal : | 0 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 0 | |||
| 52-week | High : | 3.57 | Low : | 3.31 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ THAR ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Tharimmune, Inc. is a biotechnology firm operating in the clinical stage, focused on creating therapeutic solutions for rare, inflammatory, and oncological conditions. Its preclinical immuno-oncology portfolio includes several product candidates: TH104, aimed at treating inflammatory conditions linked to the liver and other causes of itching; TH3215 and TH0059, which are designed to address a variety of solid tumors; and TH1940, specifically targeting programmed cell death protein 1 (PD-1). Furthermore, the company has entered into a research collaboration and product license agreement with Minotaur Therapeutics, Inc. to develop proprietary targeted biologics. Originally incorporated in 2017 as Hillstream BioPharma, Inc., the company rebranded to Tharimmune, Inc. in September 2023 and maintains its headquarters in Bridgewater, New Jersey.
Wed, 13 May 2026
Canton Strategic Holdings Releases Q1 2026 Financial Results - AlphaStreet
Tue, 17 Feb 2026
Is Canton’s price set to explode amid Tharimmune’s rebrand? - Bitget
Tue, 17 Feb 2026
Tharimmune rebrands as Canton Strategic Holdings with new ticker CNTN - Investing.com
Thu, 29 Jan 2026
THAR Price Today: Tharimmune, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Fri, 23 Jan 2026
Tharimmune And The Canton Network: A Privacy Focused, Asymmetric Bet On Tokenization - Seeking Alpha
Sat, 22 Nov 2025
Crypto Company Creates Bizarre Drug - Futurism
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|